Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization

被引:10
作者
Dosquet, C
Chen, Y
Makke, J
Miclea, JM
Coudert, MC
Marolleau, JP
Fermand, JP
Cottu, P
Lotz, JP
Benbunan, M
机构
[1] Hop St Louis, Cell Therapy Unit, F-75475 Paris 10, France
[2] Hop St Louis, Dept Hematol & Oncol, F-75475 Paris, France
[3] Tenon Hosp, Dept Oncol, Paris, France
关键词
D O I
10.1046/j.1537-2995.2001.41020206.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The mechanism of HPC mobilization in humans is unclear. In this study, the relationship between PBPC mobilization and blood levels of G-CSF, endogenous cytokines (IL-8, SCF, thrombopoietin [TPO]), and the vascular cell adhesion molecule-1 (VCAM-1) was analyzed in patients with malignancy who were undergoing a PBPC mobilization regimen. STUDY DESIGN AND METHODS: Fifty-four patients with multiple myeloma (MM) and 29 with breast cancer (BC) underwent a mobilization regimen combining conventional chemotherapy and G-CSF up to the last day of PBPC collection. The CD34+ cell count was determined on each day when leukapheresis was scheduled. Venous blood samples (n = 117) were drawn before apheresis for CD34+ cell count (flow cytometry) and cytokine (G-CSF, IL-8, SCF, TPO) and VCAM-1 measurements (ELISA). RESULTS: In multiple regression analysis, SCF was a significant determinant of CD34+ cell levels in BC patients (R = 0.50, p = 0.03) and of VCAM-1 levels in MM patients (R = 0.32, p = 0.02). SCF was negatively correlated with CD34+ cell count in patients with BC. SCF and VCAM-1 blood levels were correlated in MM and BC patients. CONCLUSION: SCF and VCAM-1 could play a role in PBPC mobilization in patients and could be useful measures by which to study patients undergoing a mobilization regimen.
引用
收藏
页码:206 / 212
页数:7
相关论文
共 36 条
[11]  
Dosquet C, 1997, CLIN CANCER RES, V3, P2451
[12]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[13]  
2-U
[14]   Endogenous thrombopoietin serum levels during multicycle chemotherapy [J].
Engel, C ;
Loeffler, M ;
Franke, H ;
Schmitz, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (03) :832-838
[15]   G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective [J].
Faulkner, LB ;
Tucci, F ;
Tamburini, A ;
Tintori, V ;
Lippi, AA ;
Bambi, F ;
Malentacca, F ;
Azzari, C ;
Gelli, AMG ;
Genovese, F ;
Bernini, G .
BONE MARROW TRANSPLANTATION, 1998, 21 (11) :1091-1095
[16]   CIRCULATING ADHESION MOLECULES IN DISEASE [J].
GEARING, AJH ;
NEWMAN, W .
IMMUNOLOGY TODAY, 1993, 14 (10) :506-512
[17]   DEVELOPMENT OF A SIMPLIFIED SINGLE-APHERESIS APPROACH FOR PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PREVIOUSLY TREATED PATIENTS WITH LYMPHOMA [J].
JONES, HM ;
JONES, SA ;
WATTS, MJ ;
KHWAJA, A ;
MILLS, W ;
FIELDING, A ;
GOLDSTONE, AH ;
LINCH, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1693-1702
[18]   Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8 [J].
Laterveer, L ;
Lindley, IJD ;
Heemskerk, DPM ;
Camps, JAJ ;
Pauwels, EKJ ;
Willemze, R ;
Fibbe, WE .
BLOOD, 1996, 87 (02) :781-788
[19]  
Mohle R, 1995, EXP HEMATOL, V23, P1535
[20]  
Molineux Graham, 1998, P713